A novel in silico approach to drug discovery via computational intelligence - PubMed

Affiliations

• PMID: 19348414
• DOI: 10.1021/ci9000647

A novel in silico approach to drug discovery via computational intelligence

David Hecht et al. J Chem Inf Model. 2009 Apr.

Abstract

A computational intelligence drug discovery platform is introduced as an innovative technology designed to accelerate high-throughput drug screening for generalized protein-targeted drug discovery. This technology results in collections of novel small molecule compounds that bind to protein targets as well as details on predicted binding modes and molecular interactions. The approach was tested on dihydrofolate reductase (DHFR) for novel antimalarial drug discovery; however, the methods developed can be applied broadly in early stage drug discovery and development. For this purpose, an initial fragment library was defined, and an automated fragment assembly algorithm was generated. These were combined with a computational intelligence screening tool for prescreening of compounds relative to DHFR inhibition. The entire method was assayed relative to spaces of known DHFR inhibitors and with chemical feasibility in mind, leading to experimental validation in future studies.

Similar articles

• In silico screening against wild-type and mutant Plasmodium falciparum dihydrofolate reductase.

  Fogel GB, Cheung M, Pittman E, Hecht D. Fogel GB, et al. J Mol Graph Model. 2008 Apr;26(7):1145-52. doi: 10.1016/j.jmgm.2007.10.006. Epub 2007 Oct 18. J Mol Graph Model. 2008. PMID: 18037315

• Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.

  Schormann N, Senkovich O, Walker K, Wright DL, Anderson AC, Rosowsky A, Ananthan S, Shinkre B, Velu S, Chattopadhyay D. Schormann N, et al. Proteins. 2008 Dec;73(4):889-901. doi: 10.1002/prot.22115. Proteins. 2008. PMID: 18536013

• Towards in silico lead optimization: scores from ensembles of protein/ligand conformations reliably correlate with biological activity.

  Popov VM, Yee WA, Anderson AC. Popov VM, et al. Proteins. 2007 Feb 1;66(2):375-87. doi: 10.1002/prot.21201. Proteins. 2007. PMID: 17078091

• The synergy between combinatorial chemistry and high-throughput screening.

  Diller DJ. Diller DJ. Curr Opin Drug Discov Devel. 2008 May;11(3):346-55. Curr Opin Drug Discov Devel. 2008. PMID: 18428088 Review.

• The devil is still in the details--driving early drug discovery forward with biophysical experimental methods.

  Lundqvist T. Lundqvist T. Curr Opin Drug Discov Devel. 2005 Jul;8(4):513-9. Curr Opin Drug Discov Devel. 2005. PMID: 16022188 Review.

Cited by

• Template-based de novo design for type II kinase inhibitors and its extented application to acetylcholinesterase inhibitors.

  Su BH, Huang YS, Chang CY, Tu YS, Tseng YJ. Su BH, et al. Molecules. 2013 Oct 31;18(11):13487-509. doi: 10.3390/molecules181113487. Molecules. 2013. PMID: 24184819 Free PMC article.

• Modeling the evolution of drug resistance in malaria.

  Hecht D, Fogel GB. Hecht D, et al. J Comput Aided Mol Des. 2012 Dec;26(12):1343-53. doi: 10.1007/s10822-012-9618-2. Epub 2012 Nov 21. J Comput Aided Mol Des. 2012. PMID: 23179493 Free PMC article.

• In silico study of fucoxanthin as a tumor cytotoxic agent.

  Januar HI, Dewi AS, Marraskuranto E, Wikanta T. Januar HI, et al. J Pharm Bioallied Sci. 2012 Jan;4(1):56-9. doi: 10.4103/0975-7406.92733. J Pharm Bioallied Sci. 2012. PMID: 22368399 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • American Chemical Society

• Other Literature Sources

  • The Lens - Patent Citations Database